HANDLE-a Real World Study on Satralizumab in NMOSD
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12+
SponsorHuashan Hospital
About this trial
This study is a single-center, retrospective-prospective, non-interventional cohort study to assess the clinical outcomes of Chinese NMOSD patients treated with satralizumab in a real-world patient management model by collecting follow-up data in clinical practice.
Eligibility criteria
Qualifiers
Patients have been diagnosed with NMOSD and tested seropositive for AQP4 antibody, ≥ 12 years old;
EDSS score ≤ 8.5 at baseline;
Patients have experienced ≥ 1 relapse of NMOSD in the last 12 months or ≥ 2 relapses in the last 24 months;
Patients should have received or be anticipated to receive satralizumab treatment for at least 12 months;
Disqualifiers
None
Trial design
Treatments tested in this trial
- Satralizumab
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov